NCT03455270: G1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast Cancer

NCT03455270
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have ER++ tumor(s)
Exclusions: Active uncontrolled/symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03455270

Comments are closed.

Up ↑